JP2022513626A5 - - Google Patents

Info

Publication number
JP2022513626A5
JP2022513626A5 JP2021529265A JP2021529265A JP2022513626A5 JP 2022513626 A5 JP2022513626 A5 JP 2022513626A5 JP 2021529265 A JP2021529265 A JP 2021529265A JP 2021529265 A JP2021529265 A JP 2021529265A JP 2022513626 A5 JP2022513626 A5 JP 2022513626A5
Authority
JP
Japan
Prior art keywords
fusion polypeptide
seq
sequence
tag
polypeptide according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021529265A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022513626A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2019/060140 external-priority patent/WO2020109978A1/en
Publication of JP2022513626A publication Critical patent/JP2022513626A/ja
Publication of JP2022513626A5 publication Critical patent/JP2022513626A5/ja
Pending legal-status Critical Current

Links

JP2021529265A 2018-11-26 2019-11-25 Ｌｐｌ－ｇｐｉｈｂｐ１融合ポリペプチド Pending JP2022513626A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862771359P 2018-11-26 2018-11-26
US62/771,359 2018-11-26
PCT/IB2019/060140 WO2020109978A1 (en) 2018-11-26 2019-11-25 Lpl-gpihbp1 fusion polypeptides

Publications (2)

Publication Number Publication Date
JP2022513626A JP2022513626A (ja) 2022-02-09
JP2022513626A5 true JP2022513626A5 (enExample) 2022-12-05

Family

ID=68807212

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021529265A Pending JP2022513626A (ja) 2018-11-26 2019-11-25 Ｌｐｌ－ｇｐｉｈｂｐ１融合ポリペプチド

Country Status (5)

Country Link
US (1) US20220025344A1 (enExample)
EP (1) EP3887393A1 (enExample)
JP (1) JP2022513626A (enExample)
CN (1) CN113396158A (enExample)
WO (1) WO2020109978A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117384912A (zh) * 2023-12-13 2024-01-12 中国人民解放军东部战区总医院 Gpihbp1突变型基因及其应用
WO2025124559A1 (zh) * 2023-12-13 2025-06-19 维亚臻生物技术（苏州）有限公司 捕获探针、含有其的家族性乳糜微粒血症综合征检测试剂盒及应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
WO1990006952A1 (fr) 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Facteur de stimulation de colonies de granulocytes modifies chimiquement
ATE92107T1 (de) 1989-04-29 1993-08-15 Delta Biotechnology Ltd N-terminale fragmente von menschliches serumalbumin enthaltenden fusionsproteinen.
FR2650598B1 (fr) 1989-08-03 1994-06-03 Rhone Poulenc Sante Derives de l'albumine a fonction therapeutique
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
FR2686901A1 (fr) 1992-01-31 1993-08-06 Rhone Poulenc Rorer Sa Nouveaux polypeptides antithrombotiques, leur preparation et compositions pharmaceutiques les contenant.
EP2213743A1 (en) 2000-04-12 2010-08-04 Human Genome Sciences, Inc. Albumin fusion proteins
ITMI20011483A1 (it) 2001-07-11 2003-01-11 Res & Innovation Soc Coop A R Uso di composti come antagonisti funzionali ai recettori centrali deicannabinoidi
IL161677A0 (en) 2001-11-08 2004-09-27 Protein Design Labs Stable liquid pharmaceutical formulation of igg antibodies
BR122019021416A2 (enExample) 2003-09-19 2019-12-21
US8476239B2 (en) 2005-12-20 2013-07-02 Bristol-Myers Squibb Company Stable protein formulations
SI2173890T1 (sl) 2007-06-21 2011-06-30 Univ Muenchen Tech Biološko aktivni proteini, ki imajo povečano in vivo in/ali in vitro stabilnost
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
US9221882B2 (en) 2010-05-21 2015-12-29 Technische Universitat Munchen Biosynthetic proline/alanine random coil polypeptides and their uses
AR087329A1 (es) * 2011-06-17 2014-03-19 Regeneron Pharma Anticuerpos humanos contra proteina 3 de tipo angiopoietina humana
WO2015191781A2 (en) 2014-06-10 2015-12-17 Amgen Inc. Apelin polypeptides
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
US11090310B2 (en) * 2016-07-28 2021-08-17 The Regents Of The University Of California Methods and compositions for treating hypertriglyceridemia

Similar Documents

Publication Publication Date Title
JP5524049B2 (ja) 目的ペプチドの血漿中半減期延長作用を有するペプチド
JP2023522249A5 (enExample)
RU2567667C2 (ru) Конъюгаты для введения биологически активных соединений
JP2019137675A5 (enExample)
CN108992661B (zh) 一种多肽在制备静脉、腹腔或鼻腔给药药物中的应用
TW201617364A (zh) 用於治療代謝異常之組成物及方法
JP2010104375A (ja) 粥状動脈硬化の治療用のペプチドベースの受動免疫療法
CN109106942B (zh) 一种可通过血脑屏障的多肽在制备药物中的应用
JP2021515037A5 (enExample)
JP2024513559A5 (enExample)
KR20110071117A (ko) 변성된 아밀로이드 베타 펩티드
JP2022513626A5 (enExample)
CN109265558B (zh) 改进型齐考诺肽在制备药物中的应用
CN109265557B (zh) 一种齐考诺肽和tat肽的融合多肽在制备药物中的应用
US8003610B2 (en) Bradykinin B2 receptor antagonist peptide from amphibian skin
JP6612063B2 (ja) 悪性神経膠腫分子標的ペプチド
CN102584976A (zh) 一种人血清淀粉样蛋白a1及其制备方法和应用
CN100413888C (zh) 可溶性多肽
US8501680B2 (en) Antagonists against interaction of PF4 and RANTES
CN109232744B (zh) 改进型齐考诺肽
CN109265556B (zh) 一种适用于静脉、腹腔或鼻腔给药的多肽
US20250042962A1 (en) Compositions targeting apoptosis-associated speck-like protein with caspase activation and recruitment domain (asc) and methods of use
US5587457A (en) Neutrophil stimulating peptides
CN109232746B (zh) 一种齐考诺肽和tat肽的融合多肽
US20260028397A1 (en) Methods of treating ankylosing spondylitis